

OPTIMISING RESOURCES WITH FARICIMAB: REAL-WORLD UTILISATION AND SAVINGS FROM VIAL SHARING

A. Herreros Fernández; R. Añez Castaño; R. Guzmán Laiz; I. García Masegosa; M:A. Meroño Saura; P. Selvi Sabater; C. Caballero Requejo; L. Rentero Redondo; E. Urbieta Sanz.

Reina Sofía Hospital

4CPS-034



BACKGROUND AND IMPORTANCE

Faricimab (**Vabysmo**[®]) is increasingly used for **retinal diseases** in routine clinical practice. Hospital Pharmacy departments need real-world evidence on utilisation patterns, persistence, and economic impact to optimise care and resources.




AIM AND OBJECTIVES

To evaluate the use of **faricimab** and its **economic impact** from the Hospital Pharmacy perspective.



MATERIALS AND METHODS

- **Observational, descriptive, and retrospective study.**
- Patients who initiated faricimab between January 2024 and June 2024 were included.
- Variables



-Age
-Sex
-Diagnosis
-Dosing schedule
-Treatment-naïve vs pretreated status
-Last prior therapy (for pretreated)


Data were extracted from the SAVAC[®] e-prescribing system and the SELENE[®] electronic health record, and analysed in Access[®]



RESULTS

116 patients were included

53.45%



46.55%

Mean age: 72.99 ± 11.22 years

Persistence by diagnosis

DME: 65% (6 months) // 60% (12 months)
AMD: 82% (6 months) // 78% (12 months)

Vial sharing (2024-Q1 2025) → €221,535 in savings

68.97% AMD
30.17% DME
0.86% RVO

Dosing schedule

44.83% **monthly**
42.4% **every two months**
12.93% **every three months**

79.31% **pretreated patients**

Aflibercept 71.74%
Ranibizumab 28.26%

Probability of continuing treatment

78% at 6 months
70% at 12 months



CONCLUSION AND RELEVANCE

- **AMD was the predominant indication**, with **monthly** and **bimonthly** schedules used most often.
 - Most patients had been **previously treated**, mainly with aflibercept.
- **Persistence** at 6 and 12 months was similar overall, with **higher persistence in AMD than DME**.
 - **Vial sharing in the Pharmacy generated substantial cost savings for the health system.**

